Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020)

OBJECTIVES: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in survival among real‐world patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Taguchi, Satoru, Kawai, Taketo, Nakagawa, Tohru, Miyakawa, Jimpei, Kishitani, Kenjiro, Sugimoto, Kazuma, Nakamura, Yu, Kamei, Jun, Obinata, Daisuke, Yamaguchi, Kenya, Kaneko, Tomoyuki, Yoshida, Kanae, Yamamoto, Sachi, Kakutani, Shigenori, Kanazawa, Koichiro, Sugihara, Yuriko, Tokunaga, Mayuko, Matsumoto, Akihiko, Uemura, Yukari, Akiyama, Yoshiyuki, Yamada, Yuta, Sato, Yusuke, Yamada, Daisuke, Enomoto, Yutaka, Nishimatsu, Hiroaki, Ishikawa, Akira, Tanaka, Yoshinori, Nagase, Yasushi, Fujimura, Tetsuya, Fukuhara, Hiroshi, Takahashi, Satoru, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles: Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087413/
https://www.ncbi.nlm.nih.gov/pubmed/35996761
http://dx.doi.org/10.1111/iju.15014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087413/
https://www.ncbi.nlm.nih.gov/pubmed/35996761
http://dx.doi.org/10.1111/iju.15014

Ejemplares similares